Rigontec
GermanyWho owns Rigontec?
Rigontec is a German Biotech company, now owned by Merck & Co, which acquired it in 2017 from Wellington Partners, NRW.BANK and 3 other investors.
Hand-verified · updated 2026-07-03
Open JSON · CC-BYKey facts
- ·Fully exited in 2017 to Merck & Co. (MSD).
- ·Average hold across 5 realized cycles: 3 years.
- ·5 distinct PE sponsors across ownership cycles.
Ownership history
5 ownership periods · co-invest detected
Wellington Partners sold Rigontec to Merck & Co. in 2017 after 3 years.
High-Tech Gruenderfonds (HTGF) sold Rigontec to Merck & Co in 2017 after 3 years.
Boehringer Ingelheim Venture Fund sold Rigontec to Merck in 2017 after 3 years.
NRW.BANK sold Rigontec to Merck in 2017 after 3 years.
Sunstone Life Science Ventures sold Rigontec to Merck & Co in 2017 after 2 years.
More from Sunstone Life Science Ventures IV
Other portfolio companies in the same fund.
Sweden
Switzerland
Finland
DenmarkMore PE-backed in Biotech
Comparable biotech deals from other GPs.
USQuestions
Who owns Rigontec?
Rigontec is now owned by Merck & Co, which acquired it in 2017 from Wellington Partners, NRW.BANK and 3 other investors.
When did Merck & Co acquire Rigontec?
Merck & Co acquired Rigontec in 2017, buying from Wellington Partners, NRW.BANK and 3 other investors.
Who did Rigontec sell to?
Wellington Partners sold Rigontec to Merck & Co. in 2017 (Trade Sale). NRW.BANK and Boehringer Ingelheim Venture Fund sold Rigontec to Merck in 2017 (Trade Sale). High-Tech Gruenderfonds (HTGF) and Sunstone Life Science Ventures sold Rigontec to Merck & Co in 2017 (Trade Sale).
Who has owned Rigontec over time?
Rigontec has been through 5 private-equity ownership periods: Wellington Partners · via Wellington Partners Life Sciences · 2014–2017 · sold to Merck & Co. · (Trade Sale); NRW.BANK · via NRW.Venture · 2014–2017 · sold to Merck · (Trade Sale); Boehringer Ingelheim Venture Fund · via Boehringer Ingelheim Venture Fund · 2014–2017 · sold to Merck · (Trade Sale); High-Tech Gruenderfonds (HTGF) · via HTGF II · 2014–2017 · sold to Merck & Co · (Trade Sale); Sunstone Life Science Ventures · via Sunstone Life Science Ventures IV · 2015–2017 · sold to Merck & Co · (Trade Sale).